According to Vision Research Reports, the global organoids market size was valued over US$ 2.19 billion in 2021 and is predicted to reach over US$ 12.7 billion by 2030, at a CAGR of 21.58 % from 2022 to 2030.
According to Vision Research Reports, the global organoids market size was valued over US$ 2.19 billion in 2021 and is predicted to reach over US$ 12.7 billion by 2030, at a CAGR of 21.58 % from 2022 to 2030.
Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/37686
Organoids are replicated or miniaturized versions of organs such as stomach, liver, lung, kidney, and brain produced from stems cells in vitro. These miniature models are three-dimensional tissue culture derived from stem cells. The stem cells are derived from pluripotent and organ specific stem cells. The global organoids market is driven by rise in prevalence of various diseases, sudden outbreak of infectious diseases in 2021, and development of organoid models for studying various disease modeling, which are expected to boost the organoids market during the forecast period. Technological advancements leading to the development of organoids for diagnosis and studying patient-derived tumors.
Increase in incidence and prevalence of chronic and infectious diseases, adoption of organoids as therapeutics tools, application of organoids in drug discovery & personalized medicine, and use of organoids in research & development is anticipated to propel the global organoids market. The globe market is driven by the application of organoids as an important tool for cell biology, gene therapy, regenerative medicine, cancer research, and disease modelling. Technological advancements are expected to propel the global organoids market during the forecast period.
Organoids are miniature, self-organized three-dimensional culture derived from stem cells, including pluripotent stem cells and adult stem cells. Organoids are considered replication of complex organs such as stomach, intestine, brain, kidney, lungs, and liver. Organoids are grown from stem cells of different sources, and these cells divide indefinitely and produce different types of cells. These structures resemble the miniature organs, which range from size of a hair width to five millimeters.
Organoids provide scientists a detailed understanding and view about the organ growth and formation, and offer them promising approach about the disease pathology and human development. Scientists have found organoids to be potential mini organs in the drug discovery and personalized medicine.
Scope of The Report
Report Coverage | Details |
Market Size in 2021 | USD 2.19 billion |
Revenue Forecast by 2030 | USD 12.7 billion |
Growth rate from 2022 to 2030 | CAGR of 21.58% |
Base Year | 2021 |
Forecast Period | 2022 to 2030 |
Segmentation | Type, Application, Source, Region |
Companies Covered | STEMCELL Technologies Inc., Cellesce Ltd., Hubrecht Organoid Technology, Definigen, 3Dnamics, Inc., Organoid Therapeutics, PeproTech, Inc., Thermo Fisher Scientific, Corning Incorporated (Life Sciences), and Merck KGgA |
Organoids as Therapeutic Tools to Drive Global Market
Organoids are considered prominent tools for discovery of drugs, diagnosis, and development of treatment for various chronic diseases. Rise in prevalence and increase in incidence of various diseases drive scientists and researchers to continue research on organoid models to study human physiology and disease modeling. Organoids are considered innovative approach for drug discovery, disease modeling through stem cell research, and innovating personalized medicines. These factors enable faster adoption of organoids as therapeutic tools across the globe. Amidst the COVID-19 pandemic, researchers are using organoids as prominent tools to study the coronavirus disease, modelling, and development of treatment. Organoids are considered powerful tools for respiratory diseases or infections. These factors are anticipated to propel the global organoids market.
Increasing Demand for Gene Mutation and Cancer Research to Drive Market
Over the past decade, organoids are being increasingly used in a range of applications, including disease modeling, pathogenesis, drug screening, and regenerative medicine, and the trend is set to continue during the forecast period. Organoid technologies have witnessed considerable developments in recent years, and continue to pave the way for the development of in vitro physiologic systems that model the origin tissues with high degree of accuracy compared to conventional approaches. The increasing focus on research and development activities is expected to play a key role in the development of the global organoids market during the assessment period.
The capability of 3D-organoid cultures to mimic organ functionality to some degree is one of the key factors likely to establish organoids as an ideal model for applications such as stem cell research to precision medicine. Furthermore, the increasing adoption of the organoid technology for use in a range of applications, including genetic mutation, gene assessment, and tumor modelling is expected to accelerate the overall development of the global organoids market during the assessment period. The assessment of different diseases by leveraging the organoid technology is anticipated to remain one of the most prominent applications of organoids in the upcoming years.
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/37686
Increasing Demand for Tumor Modelling and Biobanking to Propel Market Growth
The consistent progress in the organoid technology has gradually paved the way for ‘tumouroids’ and patient-centric 3D cultures of cells that are isolated from tumor biopsies. Over the past few decades, tumouroid lines have been established from a plethora of cancer types such as liver, breast, prostate, brain, bladder, and more from metastasis as well as primary tumors. Due to consistent advancements, in the current scenario, tumouroid lines are increasingly being passed in vitro, which opens up new avenues for a range of downstream applications. Moreover, 3D-based cultures offer additional advantages over the conventional 2D cancer-derived cell lines. Moreover, research and development activities have indicated that tumouroid culturing is highly efficient in enabling the collection of various cancer subtypes from a large pool of patients. As organoids can be easily derived and expanded from single cancer cells, the adoption of organoids to mimic intratumour diversification in culture is on the rise– a factor that is projected to propel the global organoids market during the assessment period.
New Discoveries Driven by Research & Development to Boost Prospects
Research and development activities are set to play a key role in the overall development of the global organoids market during the assessment period. In addition, increasing collaborations between researchers and medical experts are anticipated to accelerate the development of complex organoids. For instance, two recent discoveries are expected to boost the overall prospects of next-generation organoid development. The new research collaboration between a team of scientists from the Cincinnati Children’s and Japan was announced in August 2021. As per the research team, discoveries from the new research collaboration are likely to be one of the most critical aspects for the development of a new wave of complex organoids. Although the organoid technology has progressed at a consistent pace over the past few years, the application of the same continues to remain sluggish in the current scenario. However, increasing focus on the commercialization of organoids and consistent progress in genome editing techniques are expected to bolster the growth of the global organoids market during the assessment period.
Segmentation
- The global organoids market has been segmented based on type, application, source, and region
- In terms of type, the global organoids market has been classified into stomach, intestine, liver, pancreas, lung, brain, kidney, and others. The intestine segment accounted for a prominent share of the market in 2019, ascribed to rise in prevalence of inflammatory bowel diseases (IBD) across the globe. For instance, the inflammatory bowel disease (IBD) has affected 300 per 100,000 people across the world.
- Based on application, the global organoids market has been categorized into developmental biology, disease pathology of infectious disease, regenerative medicine, drug toxicity & efficacy testing, drug discovery & personalized medicine, and others. The developmental biology segment accounted for a major share of the market in 2019, owing to its consideration as primary investigative research tool of the human developmental biology. Moreover, organoids derived from embryonic stem cells offer complete understanding of the embryonic process development and insights on development of the stem cells.
- In terms of source, the global organoids market has been bifurcated into pluripotent stem cells (hIPSCs) and organ-specific adult stem cells (ASCs). The pluripotent stem cells (hIPSCs) segment dominated the global organoids market in 2019, as pluripotent stem cells are preferred for the ability to divide indefinitely for conducting basic research and has wide therapeutic applications.
Prominent Regions
The global organoids market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global organoids market in 2019, followed by Europe and Asia Pacific. The presence of prominent players conducting various studies using organoid models is a major factor boosting the growth of the organoids market in North America. In April 2021, STEMCELL Technologies, Inc. conducted projects in alliance with the University of British Columbia (UBC) at Genome British Columbia for testing thousands of FDA-approved drugs and clinical stage compounds alone or in combination for drug repurposing against SARS-CoV-2 infection by using human organoid culture technology.
The organoids market in Europe is anticipated to expand at a high CAGR from 2022F to 2030. The presence of key players offering organoids, technological advancements, large patient pool, increase in the geriatric population, and rise in prevalence of chronic diseases are anticipated to boost the growth of the organoids market in the region. Moreover, the company offers innovative portfolio of organoid models for drug screening, development of regenerative medicine, personalized medicine, and other therapeutic application. This is expected to fuel the growth of the organoids market in Europe during the forecast period.
Key Players
The global organoids market is consolidated in terms of number of players. The market is dominated by key players with innovative product offerings, robust geographic presence, and large investments in research & development. Leading players operating in the global organoids market include STEMCELL Technologies Inc., Cellesce Ltd., Hubrecht Organoid Technology, Definigen, 3Dnamics, Inc., Organoid Therapeutics, PeproTech, Inc., Thermo Fisher Scientific, Corning Incorporated (Life Sciences), and Merck KGgA. Prominent players have introduced innovative organoid models amidst the COVID-19 pandemic to study the disease pathology and develop innovative treatment. Moreover, companies are investing in continuous research & development for wide therapeutic applications.
In February 2021, Cellesce Ltd. published application of patient-derived organoids in the early cancer drug discovery, which would offer significant benefits to cancer patients. The company invests in continuous research and development for identifying tumor derived organoid as a novel solution for the drug discovery and its benefits in the cancer research.
Market Segmentation
By Type
-
- Stomach
- Intestine
- Liver
- Pancreas
- Lung
- Brain
- Kidney
- Others
By Application
-
- Developmental Biology
- Disease Pathology of Infectious Disease
- Regenerative Medicine
- Drug Toxicity and Efficacy Testing
- Drug Discovery & Personalized Medicine
- Others
By Source
-
- Pluripotent Stem Cells (hIPSCs)
- Organ-speci?c Adult Stem Cells (ASCs)
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/37686
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333